HPF vs BCYC Comparison

John Hancock Preferred Income Fund II is the United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include to invests a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.